[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals (AGIO) faces a delayed FDA decision on Pyrukynd for thalassemia, with the PDUFA date missed as labeling and REMS talks continue. This uncertainty follows mixed Phase X trial results for their sickle cell drug, impacting investor sentiment.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases and cancer.
Agios Pharmaceuticals, Inc. uses the ticker $AGIO for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Price: $XXXXX

Price Line Chart
Price 24-Hour Time-Series Raw Data
The stock price has experienced a significant decrease, primarily driven by the mixed Phase X trial results for their sickle cell drug, which failed to meet key endpoints. This negative news has overshadowed positive developments like the CHMP opinion and analyst price targets.

24-Hour: -XXXX% 7-Day: -XXXX% 30-Day: -XXXXX%

1-Year High: $XXXXX on 2025-11-18
1-Year Low: $XXXXX on 2025-11-19

AltRank: XXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Agios Pharmaceuticals, Inc. (AGIO) is currently AltRank #640 based on combined combined social and market metrics Daily Average: XXX
X Week: XXX +117
X Month: XXX -XXX
X Months: XXX +29
X Year: XXX +489
1-Year High: XXXXX on 2025-08-03
1-Year Low: X on 2024-12-29

Galaxy Score: XX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XX +1
X Month: XX +25
X Months: XX +41
X Year: XX +24
1-Year High: XX on 2025-06-26
1-Year Low: X on 2025-08-28

Engagements: XXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXX
X Week: XXXXXX +0.92%
X Month: XXXXXXX +958%
X Months: XXXXXXXXX +54%
X Year: XXXXXXXXX -XX%
1-Year High: XXXXXX on 2025-11-19
1-Year Low: XXX on 2025-04-20

Engagements by network (24h): X: XXXXX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +121%
X Months: XXXXX +61%
X Year: XXXXX -XX%
1-Year High: XXX on 2025-11-26
1-Year Low: XX on 2025-04-19

Mentions by network (24h): X: XXX

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Agios Pharmaceuticals, Inc. (AGIO) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
X Week: XXX -XX%
X Month: XXX +195%
X Months: XXXXX +194%
X Year: XXXXX +137%
1-Year High: XXX on 2025-06-28
1-Year Low: X on 2025-04-21

The most influential creators that mention Agios Pharmaceuticals, Inc. in the last XX hours

Creator Rank Followers Posts Engagements
@BiopharmIQ X XXXXXX X XXXXX
@Quantumup1 X XXXXX X XXXXX
@Biotechmaster12 X XXXXX X XXX
@Ssunten_ X XXX X XXX
@seedy19tron X XXXXX X XXX
@seedytx19 X XXXXX X XXX
@SeanValenc89161 X XX X XX
@TraderSubi95686 X X X XX
@DeepSouthDoctor X XXXXX X XX
@Trader83117 XX XXX X XX

View More

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XXX% +20%
X Month: XXX% +50%
X Months: XXX% +25%
X Year: XXX% +53%
1-Year High: XXX% on 2025-02-22
1-Year Low: XX% on 2025-09-08

Most Supportive Themes:

Most Critical Themes:

Social Dominance: XXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.011%
X Month: XXXXX% +0.015%
X Months: XXXXX% +0.013%
X Year: XXXXX% -XXXXXX%
1-Year High: XXXXX% on 2024-12-26
1-Year Low: XXXXXX% on 2025-10-24

Market Dominance: XXXXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXXXX% on 2025-03-12
1-Year Low: XXXXXXX% on 2025-11-19

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX -$1.60%
X Month: $XXXXXXXXXXXXX -$37%
X Months: $XXXXXXXXXXXXX -$19%
X Year: $XXXXXXXXXXXXX -$26%
1-Year High: $XXXXXXXXXXXXX on 2025-11-18
1-Year Low: $XXXXXXXXXXXXX on 2025-11-19

Top Agios Pharmaceuticals, Inc. Social Posts

Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"This link will never expire. Come join FDATRADING $xbi $aqst $mist $otlk $vnda $inva $axgn $bbio $agio"
X Link @Biotechmaster12 2025-12-11T23:06Z 1122 followers, XXX engagements

"If you want to be early with these trades and learn how to trade them effectively and consistently. Please come join our group. The premium is $20/month and worth well over that. $mist $axgn $agio $aqst $arwr $vnda $spy $xbi"
X Link @Biotechmaster12 2025-12-11T23:01Z 1121 followers, XXX engagements

"$EWZ $AGIO $MBOT Analyst price target for today-"
X Link @SeanValenc89161 2025-12-11T18:47Z XX followers, XX engagements

"Truist $FULC's PT to $XX reiterated at a Buy and said 'Positive Reception Permeates Around Pociredir Deserving Of Greater Valuation Credit Post Cohort 4' $CRSP - VRTX PFE $AGIO NVO NVS EMMS Truist went on to say: Positive reception is persisting around the cohort X data from the ph.Ib PIONEER study for pociredir in SCD which came in as a win for FULC with robust efficacy shown in the way of the abs. HbF bar of XX% being hit in XX% of patients showing a clear dose-response over Cohort 3b's XX% of patients. A rapid treatment delta and supportive safety profile serve as additional support. We"
X Link @Quantumup1 2025-12-11T15:24Z 3928 followers, 1298 engagements